
🚨 #FDAApproval: The @FDA has granted accelerated approval to neladalkib (Nelkarmi) for previously treated ALK-positive, locally advanced or metastatic #NSCLC. Approval was supported by the ALKOVE-1 trial. 🔗 ascopost.com/articles/2026/1…
✓News and views from the world of clinical oncology and hematology

🚨 #FDAApproval: The @FDA has granted accelerated approval to neladalkib (Nelkarmi) for previously treated ALK-positive, locally advanced or metastatic #NSCLC. Approval was supported by the ALKOVE-1 trial. 🔗 ascopost.com/articles/2026/1…

🖥️ #ASCOAI: New #ESMO26 findings highlight ASTRA, an agentic #AI system for #cholangiocarcinoma. ASTRA integrates MRI, lab data, and clinical notes to support resectability assessment in perihilar cholangiocarcinoma, improving accuracy & efficiency. 🔗 ascoai.org/articles/2026/11/…

🚨 #FDAApproval: The @FDA has granted approval for giredestrant (Wilserdly) + everolimus for adults with ER+/HER2−, ESR1-mutated advanced #BreastCancer following endocrine therapy. Approval supported by the phase III evERA Breast Cancer trial. 🔗 ascopost.com/articles/2026/1…

🫁 New research suggests surgical resection is associated with lower 3-year mortality than SABR in early-stage #NSCLC. In an analysis of 12,546 patients, mortality rates were 21.6% after surgery vs 30.3% after SABR. 🔹Richard Grieve, PhD | @JCO_ASCO 🔗 ascopost.com/news/november-2…

📑 The International Osteoporosis Foundation (@FoundationIof) has issued new guidance on bone fragility management in patients with #MGUS. Recommendations emphasize fracture risk assessment, bone evaluation, and risk-adapted treatment. Learn more ➡️ ascopost.com/news/november-2…

🔬 Researchers analyzed more than 5,000 genetic variants linked to #BreastCancer risk, identifying 709 that may influence gene activity. ➡️ The findings offer new insights into inherited #cancer susceptibility. ▪️Syed Haider, PhD | @HGGAdvances 🔗 ascopost.com/news/november-2…

🗣️Clear communication is essential as #AI becomes more integrated into #CancerCare. Patient advocate Brian A. Jones explains how transparency about AI's role can help patients feel more comfortable with its use. #ASCOQLTY26 🎥: ascoai.org/videos/newsreels/…

🥼New research involving more than 200,000 patients with advanced #cancer found that physician and practice factors had a greater influence on #ClinicalTrial participation than measured patient characteristics. ▪️@TiansterZhang | @JAMANetworkOpen 🔗 ascopost.com/news/november-2…

🔬A randomized phase II trial found that adding toripalimab to modified FOLFIRINOX improved event-free survival in borderline resectable or locally advanced #PancreaticCancer. ➡️ Median EFS: 11.1 vs 9.6 months 🔸Tingbo Liang, MD, PhD | @JCO_ASCO 🔗 ascopost.com/news/november-2…

📢 Antoinette R. Tan, MD, MHSc, FACP, FASCO (@atanmdlci), has been named inaugural Chair of the new Department of Cancer Medicine at Wake Forest University School of Medicine's (@wakeforestmed) Charlotte campus. Read the full announcement ➡️ ascopost.com/news/november-2…

👁️ New findings from phase I/II OptimUM-01 show antitumor activity with darovasertib + crizotinib as first-line therapy for metastatic #UvealMelanoma. ➡️ 34.1% objective response rate ➡️ manageable safety profile 🔹 @MeredithMcKean | @JCO_ASCO 🔗ascopost.com/news/november-2…

🖥️ #ASCOAI: Catch up on the latest news in #AI and #Oncology. 🔹 Cleo Skin earns @FDA Breakthrough Device designation 🔹 PROGRESS score stratifies metastatic #ProstateCancer risk 🔹 AI predicts MammaPrint scores from routine slides Watch the brief ▶️ ascoai.org/videos/weekly-bri…

🎗️ Five-year survival for U.S. childhood cancers rose from 60% in 1975 to 90% in 2017. A new SEER analysis highlights major advances in #PediatricOncology while revealing persistent racial and ethnic disparities. ▪️Lindsay Schwartz, MD, MS | @JNCI_Now 🔗 ascopost.com/news/november-2…

🆕 The @AmericanCancer Society has updated its #ProstateCancer screening guidelines. Key changes include PSA testing every 2 years for average-risk men ages 50–69 and annual testing for high-risk men ages 45–69. Learn about the updated guidelines ➡️ ascopost.com/news/november-2…

💻 #ASCOAI: How are #oncology professionals adopting ambient #AI scribes? Abigail Baldwin-Medsker, MBA, MSN, RN, shares findings from a prospective @MSKCancerCenter study examining clinician adoption, satisfaction, & implementation strategies. 🎥 Watch: ascoai.org/videos/newsreels/…

🫁 The phase 3️⃣ KEYNOTE-867 trial found no survival benefit from adding pembrolizumab to SBRT in unresected stage I–II #NSCLC. 📊 The combination increased toxicity, leading to early trial termination. 🔹@SalmaJabbour1 | @JCO_ASCO 🔗 ascopost.com/news/november-2…